What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?

In This Article:

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership.

AstraZeneca is a pretty big company. It has a market capitalization of UK£79b. Normally institutions would own a significant portion of a company this size. Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about AZN.

Check out our latest analysis for AstraZeneca

LSE:AZN Ownership Summary, June 10th 2019
LSE:AZN Ownership Summary, June 10th 2019

What Does The Institutional Ownership Tell Us About AstraZeneca?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that AstraZeneca does have institutional investors; and they hold 85% of the stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at AstraZeneca's earnings history, below. Of course, the future is what really matters.

LSE:AZN Income Statement, June 10th 2019
LSE:AZN Income Statement, June 10th 2019

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in AstraZeneca. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of AstraZeneca

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our data suggests that insiders own under 1% of AstraZeneca PLC in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own UK£19m of stock. In this sort of situation, it can be more interesting to see if those insiders have been buying or selling.